Cana­da hands Sanofi, Re­gen­eron their first OK for sar­ilum­ab; Rigel rais­es $40 mil­lion

• The FDA stiff-armed Sanofi and Re­gen­eron’s rheuma­toid arthri­tis drug sar­ilum­ab, but Cana­di­an of­fi­cials were hap­py to give the drug its first reg­u­la­to­ry green light. The FDA’s CRL was point­ed to some man­u­fac­tur­ing prob­lems at Sanofi, which it’s been work­ing to over­come.  But most an­a­lysts ex­pect a near-term US ap­proval.

• Cerulean $CERU went 0 for 2 in Phase II last year, forc­ing a re­struc­tur­ing that elim­i­nat­ed half of its jobs. Now the com­pa­ny — which had $38 mil­lion in cash at the end of Sep­tem­ber — is fol­low­ing up with a look at its strate­gic al­ter­na­tives.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER